AbbVie (Germany) Performance
| 4AB Stock | EUR 173.90 1.82 1.06% |
The firm shows a Beta (market volatility) of 0.31, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, AbbVie's returns are expected to increase less than the market. However, during the bear market, the loss of holding AbbVie is expected to be smaller as well. At this point, AbbVie Inc has a negative expected return of -0.0103%. Please make sure to confirm AbbVie's mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation , to decide if AbbVie Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days AbbVie Inc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, AbbVie is not utilizing all of its potentials. The latest stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 9.7 B | |
| Free Cash Flow | 24.2 B |
AbbVie |
AbbVie Relative Risk vs. Return Landscape
If you would invest 17,790 in AbbVie Inc on August 31, 2024 and sell it today you would lose (400.00) from holding AbbVie Inc or give up 2.25% of portfolio value over 90 days. AbbVie Inc is currently producing negative expected returns and takes up 2.2157% volatility of returns over 90 trading days. Put another way, 19% of traded stocks are less volatile than AbbVie, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
AbbVie Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AbbVie's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AbbVie Inc, and traders can use it to determine the average amount a AbbVie's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0046
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 4AB |
Estimated Market Risk
| 2.22 actual daily | 19 81% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AbbVie is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AbbVie by adding AbbVie to a well-diversified portfolio.
AbbVie Fundamentals Growth
AbbVie Stock prices reflect investors' perceptions of the future prospects and financial health of AbbVie, and AbbVie fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AbbVie Stock performance.
| Return On Equity | 0.72 | |||
| Return On Asset | 0.0991 | |||
| Profit Margin | 0.20 % | |||
| Operating Margin | 0.39 % | |||
| Current Valuation | 331.38 B | |||
| Shares Outstanding | 1.77 B | |||
| Price To Earning | 22.27 X | |||
| Price To Book | 18.07 X | |||
| Price To Sales | 4.72 X | |||
| Revenue | 58.05 B | |||
| EBITDA | 24.17 B | |||
| Cash And Equivalents | 5.23 B | |||
| Cash Per Share | 3.54 X | |||
| Total Debt | 59.13 B | |||
| Book Value Per Share | 9.75 X | |||
| Cash Flow From Operations | 24.94 B | |||
| Earnings Per Share | 6.25 X | |||
| Total Asset | 138.81 B | |||
About AbbVie Performance
By analyzing AbbVie's fundamental ratios, stakeholders can gain valuable insights into AbbVie's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if AbbVie has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AbbVie has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. ABBVIE INC operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 30000 people.Things to note about AbbVie Inc performance evaluation
Checking the ongoing alerts about AbbVie for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AbbVie Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AbbVie Inc generated a negative expected return over the last 90 days | |
| About 72.0% of the company shares are owned by institutions such as pension funds |
- Analyzing AbbVie's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AbbVie's stock is overvalued or undervalued compared to its peers.
- Examining AbbVie's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AbbVie's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AbbVie's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AbbVie's stock. These opinions can provide insight into AbbVie's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for AbbVie Stock analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Transaction History View history of all your transactions and understand their impact on performance |